Promising clinical results for heavily pretreated patients with colorectal cancer

Patients with KRASG12C-mutant colorectal cancer treated with Adagrasib – a KRASG12C inhibitor that irreversibly and selectively binds KRASG12C, locking it, when in active state. In this MEDtalk Jared Weiss, oncologist, presents the results of adagrasib treatment presents the promising results of adagrasib treatment